Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$108.1B
384M shares
52-week range
$267.00 – $392.55
12% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
P/S (TTM)
4.2
EV / FCF (TTM)
25.6
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
www.stryker.comNo one on the platform currently holds SYK.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 391,600 | $128.7M |
| Bridgewater Associatesas of 2026-03-31 | 26,410 | $8.7M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-09-30 | $0.8800 | 2026-10-30 |
| 2026-06-30 | $0.8800 | 2026-07-31 |
| 2026-03-31 | $0.8800 | 2026-04-30 |
| 2025-12-31 | $0.8800 | 2026-01-30 |
| 2025-09-30 | $0.8400 | 2025-10-31 |
| 2025-06-30 | $0.8400 | 2025-07-31 |
| 2025-03-31 | $0.8400 | 2025-04-30 |
| 2024-12-31 | $0.8400 | 2025-01-31 |
| 2024-09-30 | $0.8000 | 2024-10-31 |
| 2024-06-28 | $0.8000 | 2024-07-31 |
No one on the platform has traded SYK yet.
| 2024-03-27 | $0.8000 | 2024-04-30 |
| 2023-12-28 | $0.8000 | 2024-01-31 |
| Execution date | Ratio |
|---|---|
| 2004-05-17 | 2-for-1 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.1% | 12.3% | 13.8% | — | — | — |
| Rev. Growth % | 11.2% | 11.8% | ||||
| Profit Margin % | 12.9% | 13.2% | 14.0% | |||
| Free Cash Flow Margin % | 17.1% | 15.0% | 14.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +4.9% on the P/E track.
At today's price, your expected annual return is +9.9% on the P/E track.
At today's price, your expected annual return is +14.6% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $27.3B | +8.8% | $15.01 | $14.94–$15.04 | 18.8× | 16 |
| 2027 | $29.7B | +8.8% | $16.74 | $16.10–$17.13 | 16.8× | 16 |
| 2028 | $32.0B | +7.8% | $18.63 | $17.39–$19.48 | 15.1× | 7 |
| 2029 | $34.9B | +9.1% | $20.79 | $20.45–$21.52 | 13.5× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $3.49 | $3.69 | +5.7% |
| 2026-04-30 | $2.98 | $2.60 | -12.8% |
| 2026-01-29 | $4.40 | $4.47 | +1.6% |
| 2025-10-30 | $3.13 | $3.19 | +1.9% |
| 2025-07-31 | $3.07 | $3.13 | +2.0% |
| 2025-05-01 | $2.71 | $2.84 | +4.8% |
| 2025-01-28 | $3.87 | $4.01 | +3.6% |
| 2024-10-29 | $2.77 |
| $2.87 |
| +3.6% |
| $181.6B |
| — |
| HCAHCA Healthcare, Inc. | $423.82 | -0.39% | $91.8B | — |
| MCKMcKesson Corporation | $899.56 | -1.25% | $105.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$SYK hidden gem… trading close to $52 low… bought in and bought long ..
View on StockTwits ↗
$SYK after listening to the CFO comments the issues causing the sell off seem very acute and short term AND they still believe the guidance could be met. 2027 sounds very positive as well. Big overreaction in my opinion, market always over shoots. Share buy backs on the docket too
View on StockTwits ↗
$SYK never seen so much damage caused by a CFO remarks at a conference. Hopefully they can unfuck this at earnings
View on StockTwits ↗
$SYK they have to come out and reiterate the guidance or show some confidence with executive purchases or buy backs.
View on StockTwits ↗
$SYK over the next 10 years, they’re gonna get a lot of business with a lot of people getting into that age bracket. I’m a buyer. 
View on StockTwits ↗
$SYK Best opportunity to buy this in 10 years.
View on StockTwits ↗
$SYK one of the best names in med device starting to get attractive 4 hour RSI is now sub 15 $SPY
View on StockTwits ↗
$SYK 8 day drop with RSI in oversold territory. This is moving higher.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.